Fairvalue-Calculator Fairvalue-Calculator
EN DE

Bafna Pharmaceuticals Limited (BAFNAPH) Fair Value & Analysis

Healthcare · IN · Market cap ₹4.6B

Price₹194.68
Fair Value₹79.77
Upside-59.0%
Quality93/100
Evidence: High Range ₹59.82 – ₹99.71

Fair value as of: Jun 29, 2026

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Bafna Pharmaceuticals Limited (BAFNAPH) currently trades at ₹194.68, while our model-based Fair Value estimate is ₹79.77 — implying the stock looks roughly 59.0% overvalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited is a subsidiary of SRJR Lifesciences LLP.

Open the full interactive analysis →

Similar stocks

Jiangsu Hengrui Pharmaceuticals Co (600276) -44% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -75% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -78% Swedish Orphan Biovitrum AB (SOBI) -34%

Frequently asked questions

Is Bafna Pharmaceuticals Limited (BAFNAPH) undervalued?
As of Jun 29, 2026, our model estimates a fair value of ₹79.77 versus a price of ₹194.68 — about −59% (overvalued). Model-based estimate, not financial advice.
What is the fair value of BAFNAPH?
Our 21-model fair value for Bafna Pharmaceuticals Limited is ₹79.77 (as of Jun 29, 2026), built from audited fundamentals. The current price is ₹194.68.
What is the quality score of BAFNAPH?
Bafna Pharmaceuticals Limited has a Quality Score of 93/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.